Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Strong Multi‑Year Share Price Gains?
- If you are wondering whether Catalyst Pharmaceuticals at around US$24.94 is still sensibly priced or already stretched, you are not alone.
- The stock has returned 1.0% over the past week, 2.2% over the last 30 days, 7.7% year to date and 13.1% over the past year, while the 3 year return sits at 41.0% and the 5 year return is around 5x.
- These moves sit against a backdrop of ongoing attention on rare disease treatments and licensing focused companies like Catalyst Pharmaceuticals, with investors closely watching how the pipeline and commercial execution evolve. For many holders, recent price action is as much about reassessing risk as it is about potential long term growth in the business model.
- On Simply Wall St’s 6 point value check,…
Source link
